Evaluation of dry eye and meibomian gland disfunction with meibography in patients with vitiligo
Session Details
Session Title: Imaging II
Session Date/Time: Tuesday 13/09/2016 | 14:00-16:00
Paper Time: 14:40
Venue: Hall C1
First Author: : P.Kıyat TURKEY
Co Author(s): : M. Palamar I. Ertam A. Yagci
Abstract Details
Purpose:
To evaluate the dry eye tests and meibography of patients with vitiligo.
Setting:
Ege University Hospital Department of Ophtalmology, Izmir/Turkey
Methods:
Forty eyes of 20 patients with vitiligo and 40 eyes of 20 age-sex matched healthy volunteers as controls were included. All patients and healthy volunteers had undergone a comprehensive ophtalmic examination including corneal and conjunctival fluorescein staining and Oxford scoring, tear film break-up time measuring, Schirmer 1 test, Ocular Surface Disease Index score assessment, upper and lower eyelid meibomian gland evaluation using infrared captures of a biomicroscope.
Partial or complete loss of the meibomian glands (meibomian dropout) was scored for each eyelid from grade 0(no loss) through grade 3 (lost area was >2/3 of the total meibomian gland area).
Results:
The mean ages of vitiligo patiens and healthy volunteers were 35.5 ± 13.4 (range, 8-54), and 35.2 ± 12.4 years (range, 8-52), respectively (p=0.942).
Mean Schirmer 1 value and tear film break up-time were lower and Ocular Surface Disease Index score and meiboscores of lower eyelids were higher in vitiligo patients but the difference was not statistically significant (p=0.464, p=0.126, p=0.077,p=0.150, respectively).
Oxford scale score, meiboscores of upper eyelids and total (upper+lower) eyelids were significantly higher in vitiligo patients than in controls (p=0.024, p<0.001, p=0.001 respectively).
Conclusions:
Vitiligo can be associated with dry eye and there are significant differences in meibomian gland morphology in patients with vitiligo when compared with those without. For this reason patients with vitiligo should be monitored for dry eye and promptly start treatment when needed.
Financial Disclosure:
NONE